Literature DB >> 26424307

A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity.

Takaaki Murakami1, Takeshi Usui, Akio Nakajima, Yuki Mochida, Sumio Saito, Takuo Nambu, Tomoko Kato, Yuki Matsuda, Shin Yonemitsu, Seiji Muro, Shogo Oki.   

Abstract

A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a three-year outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and multiple glucagonomas. The glucagonomas may have affected his glycemic control. However, he did not demonstrate weight loss, suggesting that the patient's obesity could have obscured the early diagnosis of a glucagonoma. Genetic testing revealed a novel missense mutation at codon 561 in exon 10, resulting in an amino acid substitution from methionine to arginine (M561R) in the MEN1 gene. This mutation appeared to be responsible for the MEN1 pathogenicity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26424307     DOI: 10.2169/internalmedicine.54.4886

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors.

Authors:  Penghui Yang; Xuanlin Huang; Chengcai Lai; Lin Li; Tieling Li; Peide Huang; Songying Ouyang; Jin Yan; Sijie Cheng; Guanglin Lei; Zhaohai Wang; Linxiang Yu; Zhixian Hong; Ruisheng Li; Hui Dong; Cheng Wang; Yinghao Yu; Xuan Wang; Xianghong Li; Liming Wang; Fudong Lv; Ye Yin; Huanming Yang; Jianxun Song; Qiang Gao; Xiliang Wang; Shaogeng Zhang
Journal:  Int J Cancer       Date:  2019-05-17       Impact factor: 7.396

2.  Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1.

Authors:  Takaaki Murakami; Takeshi Usui; Yuji Nakamoto; Akio Nakajima; Yuki Mochida; Sumio Saito; Takahiro Shibayama; Nobuhisa Yamazaki; Tomonobu Hatoko; Tomoko Kato; Shin Yonemitsu; Seiji Muro; Shogo Oki
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.